• Skylight Health Group (SLHG) has announced a non-brokered private placement for gross proceeds of up to $2 million
  • The company will issue up to 2,000 debenture units at $1,000 per unit
  • Each debenture will bear an annual interest rate of 8 per cent, paid quarterly in shares
  • The proceeds from the offering will be used for general working capital purposes
  • Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health and laboratory/diagnostic testing
  • Skylight Health Group Inc. (SLHG) opened trading at $0.7369

Skylight Health Group (SLHG) has announced a non-brokered private placement for gross proceeds of up to $2 million.

The company will issue up to 2,000 debenture units at $1,000 per unit.

Each debenture will bear an annual interest rate of 8 per cent, paid quarterly in shares, and shall have a maturity date of February 15, 2025.

Each debenture shall be convertible into 1,111 common shares at C$0.90. Each debenture holder shall also receive 1,111 share purchase warrants. Each warrant entitles the holder to purchase one common share for a period 24 months.

The proceeds from the offering will be used for general working capital purposes.

The offering is expected to close on or about August 15, 2022.

Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health and laboratory/diagnostic testing.

Skylight Health Group Inc. (SLHG) opened trading at $0.7369.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

Reliq Health expands contract with U.S. health group

Reliq Health Technologies (TSXV:RHT) reveals it has expanded an existing contract with a large U.S. health group.

Telo Genomics and Emery Pharma collaborate

Telo Genomics (TSXV:TELO) collaborates with Emery Pharma to enhance cellular and molecular bioanalytical solutions for clinical research.